Chenggang Li1, Zhiming Zhao2, Zhipeng Zhou2, Rong Liu2. 1. Department of Surgical Oncology, Chinese PLA General Hospital, 28#, Fuxing Road, Beijing, 100853, People's Republic of China. drchengg@126.com. 2. Department of Surgical Oncology, Chinese PLA General Hospital, 28#, Fuxing Road, Beijing, 100853, People's Republic of China.
Abstract
BACKGROUND: Pyruvate kinase isoenzyme M2 (PKM2) is an essential enzyme involved in the regulation of aerobic glycolysis in cancer cells and promotes the translation between glycolytic flux and biosynthesis of cellular building blocks. AIM: Our present study aims to explore the expression pattern and underlying cellular functions of PKM2 in pancreatic ductal adenocarcinoma (PDAC) under metabolic stress. METHODS: Oncomine database and a tissue microarray (n = 90) were used to investigate the expression pattern of PKM2 and its clinicopathological findings. In vitro proliferation, apoptosis and invasion assays were used to determine the role and related mechanism of PKM2 in PDAC. RESULTS: Data from Oncomine database and our tissue microarray show that PKM2 is significantly elevated in PDAC specimens compared with the corresponding normal tissues. Kaplan-Meier survival analysis shows that higher expression of PKM2 is closely correlated with a poor prognosis of patients with PDAC. Under metabolic stress, suppression of PKM2 expression in PANC-1 and AsPC-1 cells results in decreased cell survival, increased caspase-3/7 activity, and reduced invasive potential, and these effects can be reversed by reintroduction of PKM2. Furthermore, sh-PKM2 cells show a significant decreased Warburg effect compared with sh-Ctrl cells as demonstrated by reduced glucose consumption and lactate production. Treatment with 2-deoxy-D-glucose, a glycolysis inhibitor, completely blocks the influences of PKM2 on cell survival and invasion. CONCLUSIONS: Our study reveals that silencing of PKM2 exhibits a tumor-suppressive role through altered Warburg effect and suggests that targeting PKM2 might serve as a potential therapeutic target for PDAC.
BACKGROUND:Pyruvate kinase isoenzyme M2 (PKM2) is an essential enzyme involved in the regulation of aerobic glycolysis in cancer cells and promotes the translation between glycolytic flux and biosynthesis of cellular building blocks. AIM: Our present study aims to explore the expression pattern and underlying cellular functions of PKM2 in pancreatic ductal adenocarcinoma (PDAC) under metabolic stress. METHODS: Oncomine database and a tissue microarray (n = 90) were used to investigate the expression pattern of PKM2 and its clinicopathological findings. In vitro proliferation, apoptosis and invasion assays were used to determine the role and related mechanism of PKM2 in PDAC. RESULTS: Data from Oncomine database and our tissue microarray show that PKM2 is significantly elevated in PDAC specimens compared with the corresponding normal tissues. Kaplan-Meier survival analysis shows that higher expression of PKM2 is closely correlated with a poor prognosis of patients with PDAC. Under metabolic stress, suppression of PKM2 expression in PANC-1 and AsPC-1 cells results in decreased cell survival, increased caspase-3/7 activity, and reduced invasive potential, and these effects can be reversed by reintroduction of PKM2. Furthermore, sh-PKM2 cells show a significant decreased Warburg effect compared with sh-Ctrl cells as demonstrated by reduced glucose consumption and lactate production. Treatment with 2-deoxy-D-glucose, a glycolysis inhibitor, completely blocks the influences of PKM2 on cell survival and invasion. CONCLUSIONS: Our study reveals that silencing of PKM2 exhibits a tumor-suppressive role through altered Warburg effect and suggests that targeting PKM2 might serve as a potential therapeutic target for PDAC.
Authors: Barbara Chiavarina; Diana Whitaker-Menezes; Ubaldo E Martinez-Outschoorn; Agnieszka K Witkiewicz; Ruth Birbe; Anthony Howell; Richard G Pestell; Johanna Smith; Rene Daniel; Federica Sotgia; Michael P Lisanti Journal: Cancer Biol Ther Date: 2011-12-15 Impact factor: 4.742
Authors: Nana-Maria Grüning; Mark Rinnerthaler; Katharina Bluemlein; Michael Mülleder; Mirjam M C Wamelink; Hans Lehrach; Cornelis Jakobs; Michael Breitenbach; Markus Ralser Journal: Cell Metab Date: 2011-09-07 Impact factor: 27.287
Authors: Agnieszka A Kendrick; Johnathon Schafer; Monika Dzieciatkowska; Travis Nemkov; Angelo D'Alessandro; Deepika Neelakantan; Heide L Ford; Chad G Pearson; Colin D Weekes; Kirk C Hansen; Elan Z Eisenmesser Journal: Oncotarget Date: 2017-01-24
Authors: Alissandra L Hillis; Allison N Lau; Camille X Devoe; Talya L Dayton; Laura V Danai; Dolores Di Vizio; Matthew G Vander Heiden Journal: Cancer Metab Date: 2018-10-23